hl217
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Aug 31, 2016 (NCT03650608)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Platelet-derived growth factor subunit AANTAGONIST
PDGFA antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03648346 | Phase 1 | Apr 4, 2018 | Eurofins, Hanlim Pharm. Co., Ltd. |
| NCT03650608 | Phase 1 | Aug 31, 2016 | Bio-Kinetic Clinical Applications, Hanlim Pharm. Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hanlim Pharm. Co., Ltd. | For profit | 2 | 2 | 1 | 2016 |
| Bio-Kinetic Clinical Applications | For profit | 1 | 0 | 1 | 2016 |
| Eurofins | For profit | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1